ERBB2 and non-small cell lung carcinoma: In the first-in-human phase I dose-escalation and expansion, ZW25 was evaluated in 46 patients (part 1) and 86 patients (part 2) with HER2 OE or HER2 AMP solid tumours (including NSCLC); the RDP2 was 20 mg/kg every 2 weeks, and the most common treatment-related AEs were diarrhoea (43%) and infusion reaction (34%), with only 3% of G3-4 of AEs.